GLP1R and cancer: Specifically, treatment with GLP‐1 RAs reduced the risk of hepatocellular (0.73 [0.64, 0.84]), colorectal (0.75 [0.66, 0.84]), gallbladder (0.55 [0.31, 0.97]), pancreatic (0.73 [0.63, 0.85]), oesophageal (0.71 [0.54, 0.92]), stomach (0.75 [0.59, 0.96]), kidney (0.86 [0.76, 0.97]), brain (0.62 [0.49, 0.79]), oral cavity (0.65 [0.45, 0.93]), and head and neck (0.68 [0.53, 0.86]) cancers.